12:00 AM
Apr 04, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Dipraglurant-IR: Phase IIa started

Addex began the double-blind, placebo-controlled, international Phase IIa ADX48621-201 trial to evaluate 50 and 100 mg dipraglurant-IR in combination with levodopa over 4 weeks in 72 patients. The trial...

Read the full 124 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >